Page last updated: 2024-11-01

nisoldipine and Diabetes Mellitus, Type 2

nisoldipine has been researched along with Diabetes Mellitus, Type 2 in 19 studies

Nisoldipine: A dihydropyridine calcium channel antagonist that acts as a potent arterial vasodilator and antihypertensive agent. It is also effective in patients with cardiac failure and angina.
nisoldipine : A racemate consisting of equimolar amounts of (R)- and (S)-nisoldipine. A calcium channel blocker, it is used in the treatment of hypertension and angina pectoris.
methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a methoxycarbonyl group at position 3, an o-nitrophenyl group at position 4, and an isobutoxycarbonyl group at position 5. The racemate, a calcium channel blocker, is used in the treatment of hypertension and angina pectoris.

Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.

Research Excerpts

ExcerptRelevanceReference
"Analysis of the 470 patients in the trial who had hypertension (base-line diastolic blood pressure, > or = 90 mm Hg) showed similar control of blood pressure, blood glucose and lipid concentrations, and smoking behavior in the nisoldipine group (237 patients) and the enalapril group (233 patients) throughout five years of follow-up."9.08The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. ( Biggerstaff, SL; Estacio, RO; Gifford, N; Hiatt, WR; Jeffers, BW; Schrier, RW, 1998)
"Nisoldipine (N) is a dihydropyridine calcium antagonist marketed as a racemic mixture and used for the treatment of hypertension."5.10Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. ( Coelho, EB; Dos Santos, NA; Geleilete, TJ; Lanchote, VL; Marques, MP, 2002)
"3 years of follow-up of 470 patients with hypertension and evaluates the effects of intensive and moderate blood pressure therapy using nisoldipine versus enalapril as the initial antihypertensive medication for nephropathy, retinopathy, and neuropathy."5.09Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. ( Estacio, RO; Gifford, N; Jeffers, BW; Schrier, RW, 2000)
"Analysis of the 470 patients in the trial who had hypertension (base-line diastolic blood pressure, > or = 90 mm Hg) showed similar control of blood pressure, blood glucose and lipid concentrations, and smoking behavior in the nisoldipine group (237 patients) and the enalapril group (233 patients) throughout five years of follow-up."5.08The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. ( Biggerstaff, SL; Estacio, RO; Gifford, N; Hiatt, WR; Jeffers, BW; Schrier, RW, 1998)
"Nisoldipine treatment in vitro significantly decreased [Ca2+]i, and significantly improved RBC-df."1.30Nisoldipine improves the impaired erythrocyte deformability correlating with elevated intracellular free calcium-ion concentration and poor glycaemic control in NIDDM. ( Adachi, T; Fujimoto, S; Fujita, J; Hamamoto, Y; Kajikawa, M; Mizuno, N; Mukai, E; Nishimura, M; Seino, Y; Takeda, T; Tsuda, K; Yu, L, 1999)

Research

Studies (19)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's12 (63.16)18.2507
2000's7 (36.84)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chonchol, M1
Dale, R1
Schrier, RW10
Estacio, R2
Marques, MP1
Coelho, EB1
Dos Santos, NA1
Geleilete, TJ1
Lanchote, VL1
Mehler, PS2
Coll, JR1
Esler, A3
Hiatt, WR2
Havranek, EP1
Estacio, RO8
Savage, S1
Johnson Nagel, N1
Feig, PU1
MacCarthy, EP1
Lukken, NJ1
Ziegler, R1
Jeffers, B1
Fujita, J2
Tsuda, K2
Obayashi, H1
Fukui, I1
Ishida, H1
Seino, Y2
Jeffers, BW2
Biggerstaff, SL1
Gifford, N2
Cutler, JA1
Osende, JI1
Walker, AM1
Molitch, ME1
Pahor, M1
Tatti, P1
Takeda, T1
Yu, L1
Fujimoto, S1
Kajikawa, M1
Nishimura, M1
Mizuno, N1
Hamamoto, Y1
Mukai, E1
Adachi, T1
Mehler, P1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
[NCT00000542]Phase 30 participants Interventional1993-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

11 trials available for nisoldipine and Diabetes Mellitus, Type 2

ArticleYear
Serum phosphorus and cardiovascular mortality in type 2 diabetes.
    The American journal of medicine, 2009, Volume: 122, Issue:4

    Topics: Antihypertensive Agents; Calcium; Cardiovascular Diseases; Cohort Studies; Comorbidity; Diabetes Mel

2009
Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus.
    European journal of clinical pharmacology, 2002, Volume: 58, Issue:9

    Topics: Adult; Antihypertensive Agents; Area Under Curve; Biomarkers; Blood Glucose; Blood Pressure; Cross-O

2002
Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes.
    Circulation, 2003, Feb-11, Volume: 107, Issue:5

    Topics: Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Cohort Studies; Comorbidity; Death

2003
Differential effects of antihypertensive agents on electrocardiographic voltage: results from the Appropriate Blood Pressure Control in Diabetes (ABCD) trial.
    American heart journal, 2003, Volume: 145, Issue:6

    Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, T

2003
The ABCD (Appropriate Blood Pressure Control in Diabetes) trial. Rationale and design of a trial of hypertension control (moderate or intensive) in type II diabetes.
    The Online journal of current clinical trials, 1993, Nov-24, Volume: Doc No 104

    Topics: Adult; Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Enalapril; Female

1993
Appropriate Blood Pressure Control in NIDDM (ABCD) Trial.
    Diabetologia, 1996, Volume: 39, Issue:12

    Topics: Adult; Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel

1996
The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension.
    The New England journal of medicine, 1998, Mar-05, Volume: 338, Issue:10

    Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Cardiovascular Dise

1998
Antihypertensive therapy in type 2 diabetes: implications of the appropriate blood pressure control in diabetes (ABCD) trial.
    The American journal of cardiology, 1998, Nov-12, Volume: 82, Issue:9B

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Cha

1998
The Fosinopril versus Amlodipine Cardiovascular Events Trial (FACET) and combination therapies.
    The American journal of cardiology, 1999, Mar-01, Volume: 83, Issue:5

    Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block

1999
Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes.
    Diabetes care, 2000, Volume: 23 Suppl 2

    Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Ty

2000
Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes.
    Kidney international, 2002, Volume: 61, Issue:3

    Topics: Adult; Aged; Albuminuria; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Diabetes

2002

Other Studies

8 other studies available for nisoldipine and Diabetes Mellitus, Type 2

ArticleYear
Nisoldipine blocks the increase of intracellular free calcium-ion concentration associated with elevated sodium-lithium countertransport activity in erythrocytes in patients with NIDDM.
    Diabetic medicine : a journal of the British Diabetic Association, 1997, Volume: 14, Issue:6

    Topics: Adult; Antiporters; Calcium; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Erythrocytes; Fema

1997
Calcium-channel blockers for hypertension--uncertainty continues.
    The New England journal of medicine, 1998, Mar-05, Volume: 338, Issue:10

    Topics: Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Cardiovascular Diseases; Diabete

1998
Calcium blockers questioned.
    Harvard health letter, 1998, Volume: 23, Issue:7

    Topics: Calcium Channel Blockers; Diabetes Mellitus, Type 2; Humans; Hypertension; Myocardial Infarction; Ni

1998
Nisoldipine and myocardial infarction.
    The New England journal of medicine, 1998, Jul-09, Volume: 339, Issue:2

    Topics: Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Enala

1998
Nisoldipine and myocardial infarction.
    The New England journal of medicine, 1998, Jul-09, Volume: 339, Issue:2

    Topics: Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Enala

1998
Nisoldipine and myocardial infarction.
    The New England journal of medicine, 1998, Jul-09, Volume: 339, Issue:2

    Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Diabetes Mellitus,

1998
Nisoldipine improves the impaired erythrocyte deformability correlating with elevated intracellular free calcium-ion concentration and poor glycaemic control in NIDDM.
    British journal of clinical pharmacology, 1999, Volume: 47, Issue:5

    Topics: Adult; Blood Glucose; Calcium; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Erythrocyte Defo

1999
Additional follow-up from the ABCD trial in patients with type 2 diabetes and hypertension.
    The New England journal of medicine, 2000, Dec-28, Volume: 343, Issue:26

    Topics: Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Cardiovascular Diseases; Diabete

2000